Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

01 July 1999

Comparison of different groups of cholesterol lowering drugs and total mortality: a meta-analysis

Adam Sterno

Med Sci Monit 1999; 5(4): SR786-793 :: ID: 504675

Abstract

Introduction: The aim of this study was to compare different groups of cholesterol lowering drugs. Material: Randomized trials were included if: (1) they lasted for 2 years or more, (2) the intention to treat total mortality data was obtainable, (3) at least one death had occurred, (4) one cholesterol lowering drug (fibrate, nicotinic acid and its derivate acipimox, resin, statin or probucol) was used, (5) they were published before the end of 1997. Computerized database (MEDLINE), references from former meta-analyses, overviews and already located trials were the source of data. Method: Meta-analysis. We used the conventional pooled odds ratio (OR) method. OR was calculated for each drug and for each group of drugs. Results: 26 trials were included. Out of all drug groups the total mortality only decreased amongst statins OR=0.76 (95% CI 0.68-0.86). Fibrates OR=1.08 (95% CI 0.97Ð1.21), nicotinic acid together with acipimox OR=0.94 (95% CI 0.81-1.09), resins OR=0.86 (95% CI 0.66-1.11) had no effect on the total mortality. We found no trials with probucol. Similar results were obtained following an additional analysis using the same methods and involving trials with the percentage of patients with unknown vital conditions (5% and no cholestyramine. These conclusions could only be valid in the case of patients with hypercholesterolemia and mixed hyperlipidemia with only moderately elevated triglyceride levels. Randomized, long term trials did not involve patients with hypertriglyceridemia and mixed hyperlipidemia with considerably elevated triglyceride levels. Conclusions: There exists a difference in the total mortality between different groups of cholesterol lowering drugs. Only statins lowered the total mortality.

Keywords: Mortality, cholesterol lowering drugs, cholesterol level

Add Comment 0 Comments

Editorial

01 March 2024 : Editorial  

Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia

Dinah V. Parums

DOI: 10.12659/MSM.944204

Med Sci Monit 2024; 30:e944204

0:00

In Press

18 Mar 2024 : Clinical Research  

Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative Study

Med Sci Monit In Press; DOI: 10.12659/MSM.944136  

0:00

21 Feb 2024 : Clinical Research  

Potential Value of HSP90α in Prognosis of Triple-Negative Breast Cancer

Med Sci Monit In Press; DOI: 10.12659/MSM.943049  

22 Feb 2024 : Review article  

Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943168  

23 Feb 2024 : Clinical Research  

A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943732  

Most Viewed Current Articles

16 May 2023 : Clinical Research  

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

17 Jan 2024 : Review article  

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

14 Dec 2022 : Clinical Research  

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750